FDA declines to expand approval of Pfizer arthritis drug

(Reuters) - U.S. health regulators declined to approve Pfizer Inc's oral rheumatoid arthritis drug Xeljanz to treat moderate to severe cases of the scaly skin condition plaque psoriasis, the drugmaker said on Wednesday.

Source: Reuters: Health - October 14, 2015 Category: Consumer Health News Tags: healthNews Source Type: news